NASDAQ:HIND

Vyome Q3 2026 Earnings Results & Report

$1.53 +0.02 (+1.32%)
As of 02:46 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Vyome reported Q3 2026 earnings on November 12, 2026. The company reported EPS of -$0.13, while revenue was $58.00 thousand.

Earnings Announcement Details

Quarter
Q3 2026
Time
After Market Closes
Conference Call
4:00 PM ET

Vyome EPS Results

Actual EPS
-$0.13
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Vyome Revenue Results

Actual Revenue
$58.00 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Vyome Q3 2026 Earnings FAQ

Vyome (NASDAQ:HIND) reported earnings of -$0.13 per share for Q3 2026. The report was announced on Thursday, November 12, 2026.

Vyome reported revenue of $58.00 thousand for Q3 2026.

Vyome Earnings Headlines

CFA: Bank of America Said THIS
On January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.tc pixel
Vyome Holdings Inc (HIND)
See More Vyome Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vyome? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vyome and other key companies, straight to your email.

About Vyome

Vyome (NASDAQ:HIND) is a biopharmaceutical company focused on developing treatments for dermatological conditions and infections. Its research has included drug candidates for skin disorders and bacterial infections, with an emphasis on addressing antimicrobial resistance.

The company’s historical development programs have included topical therapies for acne and other skin conditions. These products have been investigational candidates rather than established commercial treatments.

Vyome has had research and development roots in both the United States and India. Its work has centered on advancing potential therapies through clinical development.

View Vyome Profile